Advances in Bioscience and Biotechnology
Vol.4 No.3(2013), Paper ID 28784, 8
pages
DOI:10.4236/abb.2013.43053
HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery
Bastien Cautain, Nuria de Pedro, Maria Muñoz de Escalona, Jose R. Tormo, Olga Genilloud, Francisca Vicente
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Screening and Target Validation Department, Fundación Medina, Granada, Spain
Copyright © 2013 Bastien Cautain, Nuria de Pedro, Maria Muñoz de Escalona, Jose R. Tormo, Olga Genilloud, Francisca Vicente et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Cautain, B. , Pedro, N. , Escalona, M. , Tormo, J. , Genilloud, O. and Vicente, F. (2013) HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery.
Advances in Bioscience and Biotechnology,
4, 398-405. doi:
10.4236/abb.2013.43053.